Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Oncocross Co. Ltd. (382150:KRX), powered by AI.
Oncocross Co. Ltd. is currently trading at ₩4,670. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Oncocross Co. Ltd. on Alpha Lenz.
Oncocross Co. Ltd.'s P/E ratio is -6.4.
“Oncocross Co. Ltd. trades at a P/E of -6.4 (undervalued) with modest ROE of -52.8%. 3Y revenue CAGR of 35.1% highlights clear growth momentum.”
Ask for details →Oncocross Co. Ltd. is a prominent company operating in the biotechnology sector, with a focus on developing innovative medical and therapeutic solutions. The primary goal of this company is to research and advance treatments that address critical unmet medical needs. Specializing in areas like oncology and other life-threatening diseases, Oncocross Co. Ltd. employs cutting-edge technologies in drug discovery and development. Its role in the market is significant as it contributes to the pipeline of new drugs that may transform patient care and healthcare outcomes. By harnessing breakthroughs in science and technology, Oncocross Co. Ltd. aims to play a crucial role in the global effort to combat complex health challenges. As a player in the biotech industry, it is an important part of the pharmaceutical development ecosystem, potentially influencing the availability and types of new treatments available on the market.
“Oncocross Co. Ltd. trades at a P/E of -6.4 (undervalued) with modest ROE of -52.8%. 3Y revenue CAGR of 35.1% highlights clear growth momentum.”
Ask for details →Oncocross Co. Ltd. (ticker: 382150) is a company listed on KRX in the Technology sector (Software - Infrastructure). Market cap is $57.0B.
The current price is ₩4,670 with a P/E ratio of -6.38x and P/B of 4.26x.
ROE is -52.79% and operating margin is -2383.65%. Annual revenue is $370M.